• Heart Failure
  • Cardiovascular Clinical Consult
  • Adult Immunization
  • Hepatic Disease
  • Rare Disorders
  • Pediatric Immunization
  • Implementing The Topcon Ocular Telehealth Platform
  • Weight Management
  • Monkeypox
  • Guidelines
  • Men's Health
  • Psychiatry
  • Allergy
  • Nutrition
  • Women's Health
  • Cardiology
  • Substance Use
  • Pediatrics
  • Kidney Disease
  • Genetics
  • Complimentary & Alternative Medicine
  • Dermatology
  • Endocrinology
  • Oral Medicine
  • Otorhinolaryngologic Diseases
  • Pain
  • Gastrointestinal Disorders
  • Geriatrics
  • Infection
  • Musculoskeletal Disorders
  • Obesity
  • Rheumatology
  • Technology
  • Cancer
  • Nephrology
  • Anemia
  • Neurology
  • Pulmonology

Investigational Influenza-COVID-19 Combination Vaccine Elicits Immune Response in Older Adults: Daily Dose

Investigational Influenza-COVID-19 Combination Vaccine Elicits Immune Response in Older Adults: Daily Dose / Image Credit: ©New Africa/AdobeStock
©New Africa/AdobeStock

Patient Care brings primary care clinicians a lot of medical news every day—it’s easy to miss an important study. The Daily Dose provides a concise summary of one of the website's leading stories you may not have seen.

Last week, we reported on new data from an ongoing phase 3 clinical trial examining the safety, reactogenicity, and immunogenicity of mRNA-1083, an investigational combination vaccine against influenza and SARS-CoV-2 in development by Moderna.

The study

The randomized, observer-blind, active control clinical trial is evaluating the immunogenicity, safety, and reactogenicity of mRNA-1083 across 2 independent age‐group substudy cohorts of approximately 4000 individuals aged 65 years and older and 4000 individuals aged 50 to 64 years.

In the former subgroup, mRNA-1083 was compared to coadministered enhanced influenza vaccine, Fluzone HD (Sanofi) and in the latter to a standard dose of the influenza vaccine, Fluarix (GSK). For both age groups, mRNA-1083 was compared to a standard dose of Moderna’s Spikevax COVID-19 bivalent booster shot.

The findings

Investigators found that a single dose of the investigational mRNA-1083 elicited immune responses that were noninferior compared to the coadministered and routinely recommended licensed comparator vaccines. Across the 2 age cohorts mRNA-1083 resulted in higher immune responses that were statistically significant against 3 influenza virus strains and against SARS-CoV-2.

In the older adult cohort, overall geometric mean ratios (GMR) among those treated with mRNA 1083 vs those treated with Fluzone HD for the 3 flu strains were 1.0 or greater. The combination vaccine's GMR compared with Spikevax for the SARS-CoV-2 Omicron variant XBB.1.5 was greater than 1.5.

Moderna reported an acceptable safety and tolerability for mRNA-1038, stating the majority of solicited adverse reactions were rated grade 1 or 2 in severity and were consistent with profiles of the licensed vaccines administered in the trial. They included injection site pain, fatigue, myalgia, and headache.

Click here for more details.

Related Videos
"Vaccination is More of a Marathon than a Sprint"
Vaccines are for Kids, Booster Fatigue, and Other Obstacles to Adult Immunization
Tezepelumab Significantly Reduced Exacerbations in Patients with Severe Asthma, Respiratory Comorbidities
Document COVID Sequelae and Primary Care: An Interview with Samoon Ahmad, MD
Related Content
© 2024 MJH Life Sciences

All rights reserved.